HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boissonnas, A. Articles by Combadiere, B. Search for Related Content PubMed PubMed Citation Articles by Boissonnas, A. Articles by Combadiere, B. Pubmed/NCBI databases Substance via MeSH

Antigen Distribution Drives Programmed Antitumor CD8 Cell Migration and Determines Its Efficiency ¹

Laboratoire d’Immunologie Cellulaire, Institut National de la Santé et de la Recherche Médicale, Unité 543, Faculté de Médecine Pitié-Salpêtrière, Paris, France

Understanding both the role of tumor Ag in CD8 cell differentiation and the reasons that CD8 cells may work inefficiently is crucial for therapeutic approaches in cancer. We studied OT-1 CD8 cell responses in vivo in a differential Ag-distribution model that used EG-7, the EL-4 thymoma transfected with OVA. On their initial Ag encounter, OT-1 CD8 cells underwent programmed expansion in the lymph nodes, where they acquired the ability to migrate to the encapsulated tumor site after 4 divisions, without continuous antigenic stimulation. This short antigenic stimulation was sufficient to induce the migration differentiation program, which included modulation of chemokine receptor mRNA expression and down-regulation of CD62L. Moreover, Ag quantity determined the behavior of the OT-1 CD8 cells, including their effector functions and sensitivity to apoptosis. Thus, the initial Ag encounter drives the programmed cell migration potencies, but neither effector functions nor cell death can occur without continuous TCR triggering.

This article has been cited by other articles:

				C. E. Rolle, R. Carrio, and T. R. Malek Modeling the CD8+ T Effector to Memory Transition in Adoptive T-Cell Antitumor Immunotherapy Cancer Res., April 15, 2008; 68(8): 2984 - 2992. [Abstract] [Full Text] [PDF]

				J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor J. Immunol., June 1, 2007; 178(11): 6752 - 6760. [Abstract] [Full Text] [PDF]

				A. Boissonnas, L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor J. Exp. Med., February 19, 2007; 204(2): 345 - 356. [Abstract] [Full Text] [PDF]

				N. T. Joncker, J. Helft, A. Jacquet, V. Premel, and O. Lantz Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion. Cancer Res., May 15, 2006; 66(10): 5443 - 5451. [Abstract] [Full Text] [PDF]

				E. Lavergne, C. Combadiere, M. Iga, A. Boissonnas, O. Bonduelle, M. Maho, P. Debre, and B. Combadiere Intratumoral CC Chemokine Ligand 5 Overexpression Delays Tumor Growth and Increases Tumor Cell Infiltration J. Immunol., September 15, 2004; 173(6): 3755 - 3762. [Abstract] [Full Text] [PDF]